NASH
MCID: NNL006
MIFTS: 51

Non-Alcoholic Steatohepatitis (NASH)

Categories: Genetic diseases, Liver diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Non-Alcoholic Steatohepatitis

MalaCards integrated aliases for Non-Alcoholic Steatohepatitis:

Name: Non-Alcoholic Steatohepatitis 12 52 17
Nash 12 52
Non-Alcoholic Fatty Liver Disease 52
Nonalcoholic Steatohepatitis 52

Classifications:



External Ids:

Disease Ontology 12 DOID:0080547

Summaries for Non-Alcoholic Steatohepatitis

NIH Rare Diseases : 52 Nonalcoholic steatohepatitis , or NASH, is a common, often "silent" liver disease. It resembles alcoholic liver disease , but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis , in which the liver is permanently damaged and scarred and no longer able to work properly. NASH most often occurs in people who are middle aged and overweight or obese. Affected individuals may also have elevated levels of blood lipids (such as cholesterol and triglycerides) and many have diabetes or prediabetes . Treatment is centered around working towards a healthy lifestyle, including weight reduction, dietary modification, increased activity and avoidance of alcohol and unnecessary medications. The underlying cause of NASH remains unclear.

MalaCards based summary : Non-Alcoholic Steatohepatitis, also known as nash, is related to non-alcoholic fatty liver disease and alcohol use disorder. An important gene associated with Non-Alcoholic Steatohepatitis is INS (Insulin), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Milk thistle and Telmisartan have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and cellular

Disease Ontology : 12 A nonalcoholic fatty liver disease that is characterized by the presence of inflammation with hepatocyte injury such as ballooning, with or without any fibrosis.

Related Diseases for Non-Alcoholic Steatohepatitis

Diseases related to Non-Alcoholic Steatohepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 610)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic fatty liver disease 31.3 TNF PPARG PPARA INS IL6 GPT
2 alcohol use disorder 31.2 SLC17A5 GPT GGT1
3 liver cirrhosis 31.0 SLC17A5 GPT GGT1 ADIPOQ
4 portal hypertension 31.0 TNF INS GPT
5 gout 30.7 TNF INS IL6
6 autoimmune hepatitis 30.6 TNF SLC17A5 GPT GGT1
7 cholelithiasis 30.6 INS GPT GGT1
8 hyperuricemia 30.6 INS GPT GGT1
9 infantile liver failure syndrome 1 30.6 SLC17A5 GPT
10 wilson disease 30.6 TNF IL6 GPT
11 arteries, anomalies of 30.5 TNF INS IL6 ADIPOQ
12 hyperandrogenism 30.5 PPARG INS ADIPOQ
13 gastroesophageal reflux 30.5 TNF IL6 ADIPOQ
14 retinal vascular disease 30.5 TNF INS IL6
15 exanthem 30.5 TNF IL6 GPT
16 alcoholic hepatitis 30.5 TNF SLC17A5 IL6 GPT GGT1
17 choline deficiency disease 30.4 PPARA GPT
18 fatty liver disease, nonalcoholic 1 30.4 SLC17A5 PPARA INS GPT GGT1 ADIPOQ
19 bilirubin metabolic disorder 30.4 SLC17A5 GPT GGT1
20 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.4 INS ADIPOQ
21 chlamydia pneumonia 30.4 TNF IL6
22 coronary stenosis 30.4 PON1 IL6 ADIPOQ
23 nasopharyngitis 30.4 TNF INS GPT
24 cholestasis 30.4 SLC17A5 IL6 GPT GGT1
25 acquired generalized lipodystrophy 30.4 INS ADIPOQ
26 bone resorption disease 30.2 TNF INS IL6
27 pyelonephritis 30.2 TNF IL6 GPT
28 colorectal adenoma 30.2 TNF INS IL6
29 end stage renal failure 30.2 TNF IL6 ADIPOQ
30 thyroiditis 30.2 TNF INS IL6
31 gallbladder disease 30.2 INS GPT GGT1
32 esophageal varix 30.2 GPT GGT1
33 sclerosing cholangitis 30.2 TNF IL6 GPT GGT1
34 cholangitis, primary sclerosing 30.2 TNF IL6 GPT GGT1
35 schistosomiasis 30.2 TNF GPT GGT1
36 peripheral nervous system disease 30.2 TNF INS IL6 GPT
37 coronary artery anomaly 30.2 TNF PON1 IL6 GPT GGT1
38 congestive heart failure 30.1 TNF INS IL6
39 hepatitis a 30.1 TNF INS GPT GGT1
40 hepatic encephalopathy 30.1 TNF SLC17A5 IL6 GPT
41 hepatitis 30.1 TNF SLC17A5 GPT GGT1
42 systemic scleroderma 30.1 TNF INS IL6
43 iron deficiency anemia 30.0 TNF PON1 IL6
44 viral hepatitis 30.0 TNF SLC17A5 INS IL6 GPT GGT1
45 acute cystitis 30.0 TNF INS IL6 GPT
46 cryoglobulinemia 29.9 TNF IL6 GPT
47 hyperinsulinism 29.9 PPARG PPARA INS ADIPOQ
48 acute pancreatitis 29.9 TNF INS IL6 GPT
49 hyperglycemia 29.9 PPARG INS IL6 ADIPOQ
50 sleep apnea 29.8 TNF INS IL6 GPT ADIPOQ

Graphical network of the top 20 diseases related to Non-Alcoholic Steatohepatitis:



Diseases related to Non-Alcoholic Steatohepatitis

Symptoms & Phenotypes for Non-Alcoholic Steatohepatitis

GenomeRNAi Phenotypes related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 INS PTEN TNF

MGI Mouse Phenotypes related to Non-Alcoholic Steatohepatitis:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 ADIPOQ GGT1 IL6 INS PON1 PPARA
2 homeostasis/metabolism MP:0005376 10.18 ADIPOQ GGT1 IL6 INS PON1 PPARA
3 behavior/neurological MP:0005386 10.15 ADIPOQ GGT1 IL6 INS PPARG PTEN
4 growth/size/body region MP:0005378 10.15 ADIPOQ GGT1 IL6 INS PPARA PPARG
5 cardiovascular system MP:0005385 10.14 ADIPOQ IL6 INS PON1 PPARA PPARG
6 adipose tissue MP:0005375 10.1 ADIPOQ IL6 INS PPARA PPARG PTEN
7 immune system MP:0005387 10.06 ADIPOQ GGT1 IL6 INS PPARA PPARG
8 endocrine/exocrine gland MP:0005379 10.05 ADIPOQ GGT1 IL6 INS PPARG PTEN
9 integument MP:0010771 10.03 ADIPOQ GGT1 IL6 INS PPARA PPARG
10 mortality/aging MP:0010768 10.02 ADIPOQ GGT1 IL6 INS PPARA PPARG
11 liver/biliary system MP:0005370 9.95 ADIPOQ IL6 INS PPARA PPARG PTEN
12 muscle MP:0005369 9.87 ADIPOQ IL6 INS PPARA PPARG PTEN
13 renal/urinary system MP:0005367 9.7 ADIPOQ GGT1 IL6 INS PPARA PPARG
14 neoplasm MP:0002006 9.65 ADIPOQ IL6 PPARG PTEN TNF
15 skeleton MP:0005390 9.56 ADIPOQ GGT1 GPT IL6 INS PPARG
16 vision/eye MP:0005391 9.17 GGT1 IL6 INS PPARG PTEN SLC17A5

Drugs & Therapeutics for Non-Alcoholic Steatohepatitis

Drugs for Non-Alcoholic Steatohepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 386)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
2
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
3
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
4
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
5
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
6
Liraglutide Approved Phase 4 204656-20-2 44147092
7
Glucagon Approved Phase 4 16941-32-5
8
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
9
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
10
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
11
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
12
Insulin aspart Approved Phase 4 116094-23-6 16132418
13
Insulin detemir Approved Phase 4 169148-63-4 5311023
14
Ribavirin Approved Phase 4 36791-04-5 37542
15
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
16
Gliclazide Approved Phase 4 21187-98-4 3475
17
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
18
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
19
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
20
Glimepiride Approved Phase 4 93479-97-1 3476
21
Phentermine Approved, Illicit Phase 4 122-09-8 4771
22
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
23
Lenvatinib Approved, Investigational Phase 4 417716-92-8
24
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
25
Methyltestosterone Approved Phase 4 58-18-4 6010
26
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
27
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
28
Testosterone enanthate Approved Phase 4 315-37-7 9416
29
Alogliptin Approved Phase 4 850649-61-5 11450633
30
Dulaglutide Approved, Investigational Phase 4 923950-08-7
31
Empagliflozin Approved Phase 4 864070-44-0
32
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
33
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
34
Metformin Approved Phase 4 657-24-9 14219 4091
35
Zinc Approved, Investigational Phase 4 7440-66-6 32051
36
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
37
Insulin glargine Approved Phase 4 160337-95-1
38
Saxagliptin Approved Phase 4 361442-04-8 11243969
39
Choline Approved, Nutraceutical Phase 4 62-49-7 305
40
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
41
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
42
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
43
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
44
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
45
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
46
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
47
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
48
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
49 Tocotrienol Investigational Phase 4 6829-55-6
50 Ipragliflozin Investigational Phase 4 761423-87-4

Interventional clinical trials:

(show top 50) (show all 952)
# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
3 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
4 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
5 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
6 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
7 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
8 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
9 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
10 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
11 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
12 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
13 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
14 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
15 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
16 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
17 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
18 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
19 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
20 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
21 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
22 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
23 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
24 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
25 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
26 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
27 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
28 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
29 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
30 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
31 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
32 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
33 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
34 Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus Completed NCT01951651 Phase 4 Exenatide;Glipizide
35 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
36 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
37 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
38 Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus Completed NCT01432405 Phase 4 Exenatide;Pioglitazone
39 Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome Completed NCT01356394 Phase 4
40 Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Completed NCT01155206 Phase 4 glucagon
41 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
42 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
43 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
44 Local Anesthesia for Prostate Biopsy: Effects on Pain Control, Quality of Life, and Surgical Intervention Completed NCT00422708 Phase 4
45 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Recruiting NCT03198572 Phase 4 Placebo;Berberine
46 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
47 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Recruiting NCT02051842 Phase 4 Metadoxine
48 Silymarin® - Efficacy in Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) Controlled by Laboratory and and Elastographic Parameters Recruiting NCT02973295 Phase 4 Silymarin
49 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Recruiting NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
50 Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery Recruiting NCT03849729 Phase 4 Phentermine

Search NIH Clinical Center for Non-Alcoholic Steatohepatitis

Genetic Tests for Non-Alcoholic Steatohepatitis

Anatomical Context for Non-Alcoholic Steatohepatitis

MalaCards organs/tissues related to Non-Alcoholic Steatohepatitis:

40
Liver, Testes, Kidney, Heart, Endothelial, Bone, T Cells

Publications for Non-Alcoholic Steatohepatitis

Articles related to Non-Alcoholic Steatohepatitis:

(show top 50) (show all 8582)
# Title Authors PMID Year
1
Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease. 61
31852298 2020
2
Aquaporin-9 is involved in the lipid-lowering activity of the nutraceutical silybin on hepatocytes through modulation of autophagy and lipid droplets composition. 61
31816412 2020
3
Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis. 61
31076404 2020
4
How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. 61
32033764 2020
5
Hepatic dysfunction after spinal cord injury: A vicious cycle of central and peripheral pathology? 61
31863731 2020
6
Challenges and opportunities in drug development for nonalcoholic steatohepatitis. 61
31926994 2020
7
Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. 61
32033758 2020
8
Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis. 61
32033761 2020
9
Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. 61
32033762 2020
10
Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. 61
31690932 2020
11
New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. 61
32016853 2020
12
Role of ghrelin isoforms in the mitigation of hepatic inflammation, mitochondrial dysfunction, and endoplasmic reticulum stress after bariatric surgery in rats. 61
31324878 2020
13
CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease. 61
31709830 2020
14
Plasma metabolic alterations in patients with severe obesity and non-alcoholic steatohepatitis. 61
31825539 2020
15
Aging exacerbates high-fat diet-induced steatohepatitis through alteration in hepatic lipid metabolism in mice. 61
32030821 2020
16
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. 61
31940200 2020
17
An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. 61
32029622 2020
18
MicroRNA 223 3p Negatively Regulates the NLRP3 Inflammasome in Acute and Chronic Liver Injury. 61
31585800 2020
19
Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. 61
31651429 2020
20
[1,2,5]Oxadiazolo[3,4-b]pyrazine-5,6-diamine Derivatives as Mitochondrial Uncouplers for the Potential Treatment of Nonalcoholic Steatohepatitis. 61
32017849 2020
21
Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. 61
30506586 2020
22
H∞ Static Output-Feedback Control Design for Discrete-Time Systems Using Reinforcement Learning. 61
31021775 2020
23
PNPLA3 Polymorphism Influences The Association Between High-Normal Tsh Level And Nash In Euthyroid Adults With Biopsy-Proven Nafld. 61
32035968 2020
24
The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD. 61
31789757 2020
25
Identification of hub genes and key pathways of dietary advanced glycation end products‑induced non‑alcoholic fatty liver disease by bioinformatics analysis and animal experiments. 61
31974594 2020
26
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. 61
32027858 2020
27
Biokinetics of fed-batch production of poly (3-hydroxybutyrate) using microbial co-culture. 61
31844913 2020
28
Dealing with missing data by EM in single-case studies. 61
30805863 2020
29
Multiple Relevant Feature Ensemble Selection Based on Multilayer Co-Evolutionary Consensus MapReduce. 61
30130243 2020
30
Long-term outcomes after liver transplantation in the Hispanic population. 61
31505081 2020
31
C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes. 61
31351021 2020
32
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S. 61
31658974 2020
33
Cholesterol impairs hepatocyte lysosomal function causing M1 polarization of macrophages via exosomal miR-122-5p. 61
31759057 2020
34
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes. 61
31604692 2020
35
Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes. 61
31705834 2020
36
Baicalin attenuates hepatic injury in non-alcoholic steatohepatitis cell model by suppressing inflammasome-dependent GSDMD-mediated cell pyroptosis. 61
32028242 2020
37
HLSC-Derived Extracellular Vesicles Attenuate Liver Fibrosis and Inflammation in a Murine Model of Non-alcoholic Steatohepatitis. 61
31757759 2020
38
Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. 61
31292843 2020
39
Discovery of Novel Peroxisome Proliferator-Activated Receptor α (PPARα) Agonists by Virtual Screening and Biological Evaluation. 61
32027126 2020
40
A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. 61
32039405 2020
41
Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. 61
32015483 2020
42
Modulation of hippocampal TLR4/BDNF signal pathway using probiotics is a step closer towards treating cognitive impairment in NASH model. 61
31786271 2020
43
Protein kinase C promotes choline transporter‑like protein 1 function via improved cell surface expression in immortalized human hepatic cells. 61
31974614 2020
44
Obeticholic acid for the treatment of NASH. 61
31919473 2020
45
Decision making for liver biopsy in NASH, not so FAST? 61
32027859 2020
46
Peculiarities of Cirrhosis due to Nonalcoholic Steatohepatitis (NASH). 61
31537030 2020
47
The molecular basis for current targets of NASH therapies. 61
31847612 2020
48
Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH). 61
31868526 2020
49
NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges. 61
31984804 2020
50
Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH). 61
31985310 2020

Variations for Non-Alcoholic Steatohepatitis

Expression for Non-Alcoholic Steatohepatitis

Search GEO for disease gene expression data for Non-Alcoholic Steatohepatitis.

Pathways for Non-Alcoholic Steatohepatitis

Pathways related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.3 TNF PPARG PPARA INS IL6 ADIPOQ
2
Show member pathways
12.4 TNF PTEN INS IL6 ADIPOQ
3 12.27 PTEN PPARG INS ADIPOQ
4
Show member pathways
12 TNF INS IL6 GGT1
6
Show member pathways
11.91 PPARG INS ADIPOQ
7
Show member pathways
11.85 PTEN INS IL6
8 11.71 PTEN INS IL6
9
Show member pathways
11.65 TNF INS ADIPOQ
10
Show member pathways
11.6 TNF PTEN PPARA INS IL6
11 11.51 PPARG PPARA ADIPOQ
12 11.46 TNF PPARG IL6
13 11.42 TNF PPARA ADIPOQ
14 11.22 TNF PPARG PPARA INS IL6 ADIPOQ
15 10.83 TNF IL6
16 10.73 INS GPT
17 10.6 TNF PPARG IL6 ADIPOQ

GO Terms for Non-Alcoholic Steatohepatitis

Cellular components related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 TNF PON1 INS IL6 GPT GGT1

Biological processes related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.94 TNF PTEN INS IL6
2 positive regulation of apoptotic process GO:0043065 9.88 TNF PTEN PPARG IL6
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.82 TNF INS IL6
4 glucose homeostasis GO:0042593 9.76 PPARG INS ADIPOQ
5 cellular response to insulin stimulus GO:0032869 9.72 PTEN PPARG ADIPOQ
6 response to organic substance GO:0010033 9.71 TNF PTEN PPARG
7 response to nutrient GO:0007584 9.67 PTEN PPARG ADIPOQ
8 positive regulation of nitric-oxide synthase activity GO:0051000 9.65 TNF INS
9 regulation of fat cell differentiation GO:0045598 9.65 TNF PPARG
10 positive regulation of chemokine production GO:0032722 9.65 TNF IL6
11 positive regulation of glial cell proliferation GO:0060252 9.63 TNF IL6
12 negative regulation of phagocytosis GO:0050765 9.63 PTEN ADIPOQ
13 negative regulation of gluconeogenesis GO:0045721 9.62 INS ADIPOQ
14 negative regulation of lipid catabolic process GO:0050995 9.62 TNF INS
15 negative regulation of collagen biosynthetic process GO:0032966 9.61 PPARG IL6
16 positive regulation of cellular protein metabolic process GO:0032270 9.61 INS ADIPOQ
17 response to glucocorticoid GO:0051384 9.61 TNF IL6 ADIPOQ
18 fatty acid oxidation GO:0019395 9.6 PPARG ADIPOQ
19 positive regulation of cholesterol efflux GO:0010875 9.59 PON1 ADIPOQ
20 glucose metabolic process GO:0006006 9.58 TNF INS ADIPOQ
21 regulation of protein secretion GO:0050708 9.57 TNF INS
22 positive regulation of neuroinflammatory response GO:0150078 9.56 TNF IL6
23 negative regulation of lipid storage GO:0010888 9.52 TNF IL6
24 negative regulation of cholesterol storage GO:0010887 9.51 PPARG PPARA
25 negative regulation of fat cell differentiation GO:0045599 9.5 TNF IL6 ADIPOQ
26 negative regulation of acute inflammatory response GO:0002674 9.48 PPARG INS
27 positive regulation of fatty acid oxidation GO:0046321 9.46 PPARG PPARA
28 negative regulation of sequestering of triglyceride GO:0010891 9.37 PPARG PPARA
29 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.33 PTEN PPARG ADIPOQ
30 negative regulation of receptor biosynthetic process GO:0010871 9.26 PPARG PPARA
31 positive regulation of DNA-binding transcription factor activity GO:0051091 9.26 TNF PTEN PPARG IL6
32 negative regulation of macrophage derived foam cell differentiation GO:0010745 8.8 PPARG PPARA ADIPOQ

Sources for Non-Alcoholic Steatohepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....